Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Purpose: Salvage therapy for disseminated germ cell tumors of all histologic subtypes with vinblastine, ifosfamide, and cisplatin (VeIP) will cure approximately 25% of patients. The purpose of this study was to evaluate the activity of VeIP in patients with recurrent seminoma. Patients and Methods: We conducted a retrospective review of 24 patients with recurrent seminoma who were treated at Indiana University with VeIP as second-line chemotherapy. All patients had received cisplatin-containing regimens as primary chemotherapy and seven had also received prior pelvic radiotherapy. All patients received four courses of VeIP. Results: The minimum follow-up duration was 2 years (range, 2 to 9.1), with a median follow-up time of 7 years. Twenty of 24 patients (83%) achieved a complete remission (CR) following VeIP alone. One additional patient was rendered disease-free (NED) with the resection of residual carcinoma. Eight patients have relapsed. Four of six patients with extragonadal primary tumors and two of four who foiled to achieve CR with initial chemotherapy are continuously NED with VeIP. Overall, 13 of 24 (54%) are long-term survivors with VeIP salvage chemotherapy. Conclusion: VeIP has significant curative potential in patients with recurrent seminoma and appears to produce a higher CR rate and more long-term survivors than is achieved in patients with nonseminomatous disease.

Original languageEnglish
Pages (from-to)1427-1431
Number of pages5
JournalJournal of Clinical Oncology
Volume15
Issue number4
StatePublished - Apr 1997

Fingerprint

Ifosfamide
Seminoma
Vinblastine
Cisplatin
Drug Therapy
Survivors
Salvage Therapy
Germ Cell and Embryonal Neoplasms
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. / Miller, Kathy; Loehrer, Patrick; Gonin, R.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 15, No. 4, 04.1997, p. 1427-1431.

Research output: Contribution to journalArticle

@article{3faaa7de622443bda27c330f3d4d3b71,
title = "Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma",
abstract = "Purpose: Salvage therapy for disseminated germ cell tumors of all histologic subtypes with vinblastine, ifosfamide, and cisplatin (VeIP) will cure approximately 25{\%} of patients. The purpose of this study was to evaluate the activity of VeIP in patients with recurrent seminoma. Patients and Methods: We conducted a retrospective review of 24 patients with recurrent seminoma who were treated at Indiana University with VeIP as second-line chemotherapy. All patients had received cisplatin-containing regimens as primary chemotherapy and seven had also received prior pelvic radiotherapy. All patients received four courses of VeIP. Results: The minimum follow-up duration was 2 years (range, 2 to 9.1), with a median follow-up time of 7 years. Twenty of 24 patients (83{\%}) achieved a complete remission (CR) following VeIP alone. One additional patient was rendered disease-free (NED) with the resection of residual carcinoma. Eight patients have relapsed. Four of six patients with extragonadal primary tumors and two of four who foiled to achieve CR with initial chemotherapy are continuously NED with VeIP. Overall, 13 of 24 (54{\%}) are long-term survivors with VeIP salvage chemotherapy. Conclusion: VeIP has significant curative potential in patients with recurrent seminoma and appears to produce a higher CR rate and more long-term survivors than is achieved in patients with nonseminomatous disease.",
author = "Kathy Miller and Patrick Loehrer and R. Gonin and Lawrence Einhorn",
year = "1997",
month = "4",
language = "English",
volume = "15",
pages = "1427--1431",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma

AU - Miller, Kathy

AU - Loehrer, Patrick

AU - Gonin, R.

AU - Einhorn, Lawrence

PY - 1997/4

Y1 - 1997/4

N2 - Purpose: Salvage therapy for disseminated germ cell tumors of all histologic subtypes with vinblastine, ifosfamide, and cisplatin (VeIP) will cure approximately 25% of patients. The purpose of this study was to evaluate the activity of VeIP in patients with recurrent seminoma. Patients and Methods: We conducted a retrospective review of 24 patients with recurrent seminoma who were treated at Indiana University with VeIP as second-line chemotherapy. All patients had received cisplatin-containing regimens as primary chemotherapy and seven had also received prior pelvic radiotherapy. All patients received four courses of VeIP. Results: The minimum follow-up duration was 2 years (range, 2 to 9.1), with a median follow-up time of 7 years. Twenty of 24 patients (83%) achieved a complete remission (CR) following VeIP alone. One additional patient was rendered disease-free (NED) with the resection of residual carcinoma. Eight patients have relapsed. Four of six patients with extragonadal primary tumors and two of four who foiled to achieve CR with initial chemotherapy are continuously NED with VeIP. Overall, 13 of 24 (54%) are long-term survivors with VeIP salvage chemotherapy. Conclusion: VeIP has significant curative potential in patients with recurrent seminoma and appears to produce a higher CR rate and more long-term survivors than is achieved in patients with nonseminomatous disease.

AB - Purpose: Salvage therapy for disseminated germ cell tumors of all histologic subtypes with vinblastine, ifosfamide, and cisplatin (VeIP) will cure approximately 25% of patients. The purpose of this study was to evaluate the activity of VeIP in patients with recurrent seminoma. Patients and Methods: We conducted a retrospective review of 24 patients with recurrent seminoma who were treated at Indiana University with VeIP as second-line chemotherapy. All patients had received cisplatin-containing regimens as primary chemotherapy and seven had also received prior pelvic radiotherapy. All patients received four courses of VeIP. Results: The minimum follow-up duration was 2 years (range, 2 to 9.1), with a median follow-up time of 7 years. Twenty of 24 patients (83%) achieved a complete remission (CR) following VeIP alone. One additional patient was rendered disease-free (NED) with the resection of residual carcinoma. Eight patients have relapsed. Four of six patients with extragonadal primary tumors and two of four who foiled to achieve CR with initial chemotherapy are continuously NED with VeIP. Overall, 13 of 24 (54%) are long-term survivors with VeIP salvage chemotherapy. Conclusion: VeIP has significant curative potential in patients with recurrent seminoma and appears to produce a higher CR rate and more long-term survivors than is achieved in patients with nonseminomatous disease.

UR - http://www.scopus.com/inward/record.url?scp=0030973965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030973965&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 1427

EP - 1431

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -